(Q38180309)

30 August 2017

title

Endoglin for targeted cancer treatment (English)

1 reference

30 August 2017

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24445497%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

author name string

Lee S Rosen

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24445497%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Michael S Gordon

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24445497%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Francisco Robert

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24445497%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

publication date

1 February 2014

1 reference

30 August 2017

published in

Current Oncology Reports

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24445497%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

volume

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24445497%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24445497%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

page(s)

365

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24445497%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s11912-013-0365-x

1 June 2020

exact match

0 references

cites work

Angiogenesis in health and disease

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0365-X

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0365-X

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0365-X

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0365-X

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0365-X

Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0365-X

Mean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0365-X

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0365-X

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0365-X

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0365-X

Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0365-X

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0365-X

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0365-X

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0365-X

Pathways mediating VEGF-independent tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0365-X

Modes of resistance to anti-angiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0365-X

Distinct human leukemia-associated cell surface glycoprotein GP160 defined by monoclonal antibody SN6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0365-X

Defective angiogenesis in mice lacking endoglin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0365-X

Endoglin (CD105): a marker of tumor vasculature and potential target for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0365-X

Endoglin for tumor imaging and targeted cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0365-X

Synergy between anti-endoglin (CD105) monoclonal antibodies and TGF-beta in suppression of growth of human endothelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0365-X

CD105 prevents apoptosis in hypoxic endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0365-X

Endoglin expression is regulated by transcriptional cooperation between the hypoxia and transforming growth factor-beta pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0365-X

Endoglin has a crucial role in blood cell-mediated vascular repair.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0365-X

Hereditary Haemorrhagic Telangiectasia (HHT): genetic and molecular aspects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0365-X

Hereditary hemorrhagic telangiectasia: clinical features in ENG and ALK1 mutation carriers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0365-X

Both high intratumoral microvessel density determined using CD105 antibody and elevated plasma levels of CD105 in colorectal cancer patients correlate with poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0365-X

Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: A Gynecologic Oncology Group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0365-X

The prognostic value of endoglin (CD105) expression in ovarian carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0365-X

CD105 expression is an independent predictor of survival in patients with endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0365-X

Prognostic significance of microvessel density determined by an anti-CD105/endoglin monoclonal antibody in astrocytic tumors: comparison with an anti-CD31 monoclonal antibody.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0365-X

Correlation between CD105 expression and postoperative recurrence and metastasis of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0365-X

Endoglin expression is associated with poor oncologic outcome in oral and oropharyngeal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0365-X

Assessment of the prognostic significance of endoglin (CD105) in clear cell renal cell carcinoma using automated image analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0365-X

Regional effects of an antivascular endothelial growth factor receptor monoclonal antibody on receptor phosphorylation and apoptosis in human 253J B-V bladder cancer xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0365-X

Inhibition of c-Met reduces lymphatic metastasis in RIP-Tag2 transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0365-X

Deficiency for endoglin in tumor vasculature weakens the endothelial barrier to metastatic dissemination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0365-X

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0365-X

Genetic and pharmacological targeting of activin receptor-like kinase 1 impairs tumor growth and angiogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0365-X

Anti-tumor activity of an anti-endoglin monoclonal antibody is enhanced in immunocompetent mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0365-X

Anti-endoglin monoclonal antibodies are effective for suppressing metastasis and the primary tumors by targeting tumor vasculature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0365-X

The VHL/HIF axis in clear cell renal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0365-X

Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0365-X

Sarcoma derived from cultured mesenchymal stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0365-X

Critical role of endoglin in tumor cell plasticity of Ewing sarcoma and melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0365-X

ENDOGLIN/CD105 is expressed in KIT positive cells in the gut and in gastrointestinal stromal tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0365-X

Benign mesenchymal stromal cells in human sarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0365-X

Wilms tumor cells with WT1 mutations have characteristic features of mesenchymal stem cells and express molecular markers of paraxial mesoderm

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0365-X

Endoglin requirement for BMP9 signaling in endothelial cells reveals new mechanism of action for selective anti-endoglin antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0365-X

A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0365-X

Soluble endoglin specifically binds bone morphogenetic proteins 9 and 10 via its orphan domain, inhibits blood vessel formation, and suppresses tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0365-X

Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0365-X

Positron emission tomography imaging of CD105 expression with 89Zr-Df-TRC105.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0365-X

In vitro and in vivo effects of an anti-mouse endoglin (CD105)-immunotoxin on the early stages of mouse B16MEL4A5 melanoma tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0365-X

Identification of a tumor-initiating stem cell population in human renal carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0365-X

Comparative evaluation of microvessel density determined by CD34 or CD105 in benign and malignant gastric lesions

21 January 2018

1 reference

12 December 2020

Differential expression and cytoplasm/membrane distribution of endoglin (CD105) in human tumour cell lines: Implications in the modulation of cell proliferation

1 reference

12 December 2020

Differential expression of endoglin on fetal and adult hematopoietic cells in human bone marrow

1 reference

12 December 2020

Preoperative plasma endoglin levels predict biochemical progression after radical prostatectomy

1 reference

12 December 2020

Evaluation of angiogenesis in non-small cell lung cancer: comparison between anti-CD34 antibody and anti-CD105 antibody

1 reference

12 December 2020

A case of angiosarcoma of the breast

1 reference

12 December 2020

Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in prostatic adenocarcinoma

1 reference

12 December 2020

Expression of transforming growth factor beta and transforming growth factor beta receptors on AIDS-associated Kaposi's sarcoma

1 reference

12 December 2020

Identification of a human endothelial cell antigen with monoclonal antibody 44G4 produced against a pre-B leukemic cell line

1 reference

12 December 2020

Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide

1 reference

12 December 2020

Elevated plasma endoglin (CD105) predicts decreased response and survival in a metastatic breast cancer trial of hormone therapy

1 reference

12 December 2020

Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonal antibodies

1 reference

12 December 2020

1 reference

12 December 2020

The risk of developing metastatic disease in colorectal cancer is related to CD105-positive vessel count

1 reference

12 December 2020

Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy

1 reference

12 December 2020

Differential vascular and transcriptional responses to anti-vascular endothelial growth factor antibody in orthotopic human pancreatic cancer xenografts

1 reference

12 December 2020

Endoglin (CD105) as a prognostic factor in head and neck squamous cell carcinoma

1 reference

12 December 2020

Breast carcinoma: vascular density determined using CD105 antibody correlates with tumor prognosis

1 reference

12 December 2020

Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in esophageal adenocarcinoma

1 reference

12 December 2020